NOVARTIS

Novartis reports a Q3 net sales increase of 4% to $14.5bn and an 11% rise in core operating profit to $6.0bn; core earnings per share rose to $2.46. The company has raised its 2026 guidance for core operating results to around last year’s level up to low single-digit growth (previously a low single-digit decline). Reported operating income, however, was hit by a $1.9bn impairment on the product candidate del‑desiran, causing it to fall 59% to $1.8bn. Novartis cites lower costs and productivity improvements as support for the core result. » Más en finanzen.net

Novartis has terminated the late-stage study of remibrutinib in generalized myasthenia gravis due to an anticipated failure to meet efficacy endpoints; no safety concerns were identified. The decision does not affect ongoing studies in other indications. Novartis emphasizes that despite this setback, remibrutinib could still become the company’s highest-grossing drug; the compound is already approved as Rhapsido for chronic urticaria and also showed positive results in MS studies. » Más en finanzen.net

Novartis reported a third-quarter adjusted operating result that rose 11% to just over $6 billion and has raised its profit outlook for 2026: adjusted operating profit is now expected to either stagnate or grow in the low single digits. Group profit, however, fell by around 60% to $1.84 billion operating and $1.2 billion net due to impairments, of which $1.9 billion related to a failed Del‑Desiran study. Revenue grew 4% to about $14.5 billion, supported by older products and Cosentyx, and Novartis says it will stick to its 2025–2030 mid‑term plan despite setbacks in late‑stage trials. » Más en finanzen.net